Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEDETTE: Venetoclax and Decitabine in Relapsed/Refractory Adult T-ALL/LBL
NCT06712121Phase 2Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Jan 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, decitabine in t-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL), sponsored by Seoul National University Hospital. Started Jan 2025; status: recruiting.
02
Drugs
venetoclaxdecitabine
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT06712121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06712121.